Literature DB >> 27809624

Personalized prophylaxis in people with hemophilia A: challenges and achievements.

Muhlis Cem Ar1, Zafer Baslar1, Teoman Soysal1.   

Abstract

INTRODUCTION: Prophylactic factor replacement is the standard of care for all people with severe hemophilia to prevent bleeding and associated complications. Current weight-based fixed dose prophylaxis regimens are effective; however, they lack flexibility and usually fail to meet the individual needs and expectations of the patients. Recent developments in hemophilia treatment provide new opportunities for a more personalized prophylaxis. Areas covered: Rationale and methods of individualizing prophylaxis in hemophilia A on the basis of current evidence are discussed in this review. For this relevant literature in English and German was searched using PubMed database. Expert commentary: Major determinants of personalized prophylaxis include age, bleeding pattern, personal pharmacokinetics, joint health, co-morbidities, venous access and adherence. An ideal prophylaxis programme should take into account all of the aforementioned items and also be able to meet the needs. Extended half-life factor concentrates, new hemostatic molecules and tools using population pharmacokinetics to estimate personal factor requirements will serve individualizing prophylaxis in a more precise manner.

Entities:  

Keywords:  Hemophilia; adherence; hemophilic arthropathy; personalized prophylaxis; pharmacokinetics

Mesh:

Substances:

Year:  2016        PMID: 27809624     DOI: 10.1080/17474086.2016.1252670

Source DB:  PubMed          Journal:  Expert Rev Hematol        ISSN: 1747-4094            Impact factor:   2.929


  5 in total

1.  Real-World Clinical Outcomes and Replacement Factor VIII Consumption in Patients with Haemophilia A in Italy: A Comparison between Prophylaxis Pre and Post Octocog Alfa (BAY 81-8973).

Authors:  Paolo Angelo Cortesi; Giovanni Di Minno; Ezio Zanon; Gaetano Giuffrida; Rita Carlotta Santoro; Renato Marino; Lucia Sara D'Angiolella; Ippazio Cosimo Antonazzo; Ginevra Squassabia; Francesco Clemente; Danilo Di Laura; Ernesto Cimino; Samantha Pasca; Daniela Nicolosi; Lorenzo Giovanni Mantovani
Journal:  J Clin Med       Date:  2022-06-15       Impact factor: 4.964

2.  [Breakthrough bleeding in adult patients with severe hemophilia A receiving low- and intermediate-dose FVIII for tertiary prophylaxis: characteristics and influencing factors].

Authors:  Shi-Qiu Qiu; Jin-Mu Zhuang; Xuan Zhou; Rui-Xue Yin; Zhu-Qin Liu; Fei Ma; Ying-Jia Li; Jing Sun
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-10-20

Review 3.  Hemophilia Care in the Pediatric Age.

Authors:  Marta Bertamino; Francesca Riccardi; Laura Banov; Johanna Svahn; Angelo Claudio Molinari
Journal:  J Clin Med       Date:  2017-05-19       Impact factor: 4.241

Review 4.  Hemophilia A: Strategies for Improving Long-Term Holistic Management, Adherence, and Quality of Life.

Authors:  Miguel A Escobar; Cindy Leissinger; Guy Young
Journal:  J Adv Pract Oncol       Date:  2022-06-21

Review 5.  Personalised Prophylaxis in a Child with Haemophilia A and Type 1 Diabetes.

Authors:  Maria Sol Cruz; Josefina Santillan; Julieta Lesser; Juan Pablo Ortiz; Laura Forzani
Journal:  Clin Pract       Date:  2021-05-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.